Filing Information

Inventor(s)	James Moray Campbell · Christopher Bunce · Lyndon Gommersall · Donna Peehl ·
Assignee(s)	The University of Birmingham ·  View assignee updates
Correspondent	Paul D Greeley;Ohlandt, Greeley, Ruggiero & Perle, LLC ·
Application Number	US10592251
Filing date	03/10/2005
PCT 371 date	10/24/2008
Publication date	04/23/2009
Predicted expiration date	03/10/2025
U.S. Classifications	514/563  · 514/616  · 435/375  ·
International Classifications	A61K31164  · A61K31195  · C12N502  ·
Kind Code	A1
PCT Application Number	WO20PCTGB2005000938 - 03/10/2005
Foreign Priority	GB0405349.2 - 03/10/2004 ·

Patent Family

Abstract

The present invention relates to a novel cancer therapy, particularly, but not exclusively, to a prostate, bladder and breast cancer therapy and to Compositions and medicaments for use in said therapy. In one aspect there is provided a method of treating a patient afflicted with cancer comprising administering to the patient a therapeutically effective amount of a nuclear receptor ligand and an HDAC (histone deacetylases) inhibitor wherein said nuclear receptor ligand is not a ligand for the vitamin D receptor.

Independent Claims | See all claims (20)

1. 1-21. (canceled)
2. 22. A method of treating a patient afflicted with cancer comprising administering to the patient a therapeutically effective amount of a nuclear receptor ligand and an HDAC inhibitor wherein said nuclear receptor ligand is not a ligand for the vitamin D receptor.
3. 31. A method of reducing proliferation of or inducing programmed cell death in neoplastic cells comprising contacting said neoplastic cells with a combination of a first and a second medicament, the combination being one which up-regulates mRNA of both the nuclear receptor and at least one anti-proliferative target gene whereby to enhance antiproliferation and/or programmed cell death in said neoplastic cells, the first medicament being a nuclear receptor ligand and the second medicament being an HDAC inhibitor, except for the combination of 1α,25(OH)2D3 and TSA or NaB.
4. 35. A method of reducing proliferation and/or inducing programmed cell death of neoplastic cells exhibiting abnormal expression or activity of a co-repressor protein, comprising contacting said cells with an HDAC inhibitor and an anti-proliferative and/or programmed cell death-inducing gene trans-activating factor, whereby to induce expression of said anti-proliferative and/or programmed-cell death-inducing gene.
5. 40. A synergistic combination of an HDAC inhibitor and a nuclear receptor ligand, other than a ligand for the VDR, for reducing proliferation of or inducing programmed cell death in neoplastic cells.